Abstract 5984
Background
Xerostomia is a common symptom in cancer patients undergoing radiation to the head and neck region and/or those undergoing systemic chemotherapy. Acupuncture has been recognized as an effective integrative modality for managing xerostomia, but data about predicting treatment response to acupuncture are limited. We explored patient characteristics and treatment response among patients who received acupuncture for xerostomia.
Methods
We reviewed acupuncture records with a primary referral for xerostomia in an outpatient environment from March 2016 to April 2018. Treatment response was assessed using Edmonton Symptom Assessment Scale (ESAS; 0-10 scale) performed pre and post each acupuncture treatment. Bivariate associations between patient characteristics and treatment response were analyzed.
Results
A total of 781 acupuncture treatment records (139 patients) were identified. Majority were male (63%) and 59 (42%) with head and neck cancer. The median treatment response was 11% (IQR: 0-33) reduction in xerostomia score. BMI ≥ 35 and Charlson comorbidity index (CCI) <6 were associated with greater symptom reduction: BMI ≥ 35 (17% [IQR: 0%-100%]) vs BMI < 35 (10% [IQR: 0%-33%]), P = 0.012; CCI < 6 (14% [IQR: 0%-33%]) vs CCI ≥ 6 (0% [IQR: 0%-25%]), P = 0.003. Mental wellbeing (PROMIS Mental Health score) (P = 0.024) positively correlated with greater reduction in xerostomia score. High severity of fatigue and sleep problems correlated with less symptom reduction (P = 0.008 and P = 0.006, respectively). Higher blood glucose level was associated with less reduction (P = 0.002) in xerostomia score.
Conclusions
Using the current approach, acute pre-post treatment response of xerostomia to acupuncture was low. Features of patient clinical characteristics may be predictive of treatment response. More research is needed to further explore these associations and examine the impact of optimization of clinical conditions on acupuncture treatment response in symptom management for cancer patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4325 - Multiple synchronous mechanisms may contribute to osimertinib resistance in non-small cell lung cancer (NSCLC) patients: insights of the MATCH-R study
Presenter: Diego Enrico
Session: Poster Display session 1
Resources:
Abstract
2185 - Sequential treatment with afatinib followed by 3rd generation EGFR-TKI – subgroup analysis of the GIDEON trial: a prospective non-interventional study (NIS) in EGFR mutated NSCLC patients in Germany
Presenter: Wolfgang Brückl
Session: Poster Display session 1
Resources:
Abstract
1524 - Effectiveness of sequencing TKIs in patients with EGFR mutation-positive Non-small-Cell Lung Cancer (NSCLC): A French National medico administrative claim database analysis
Presenter: Nicolas Girard
Session: Poster Display session 1
Resources:
Abstract
5733 - Phase II study of osimertinib in NSCLC patients with EGFR exon 20 insertion mutation: A multicenter trial of the Korean Cancer Study Group (LU17-19)
Presenter: Tae Min Kim
Session: Poster Display session 1
Resources:
Abstract
5440 - Different stories for different EGFR exon 19 deletion variants
Presenter: Chao Zhao
Session: Poster Display session 1
Resources:
Abstract
2982 - Safety and activity of alflutinib in patients with advanced EGFR T790M mutation non-small cell lung cancer who progressed after EGFR-TKI therapy
Presenter: Yuan-Kai Shi
Session: Poster Display session 1
Resources:
Abstract
4002 - Afatinib followed by osimertinib in patients with EGFR mutation-positive (EGFRm+) advanced NSCLC: updated data from the GioTag real-world study
Presenter: Maximilian Hochmair
Session: Poster Display session 1
Resources:
Abstract
2941 - Treatment patterns of EGFR mt+ NSCLC IV pts: Real world data of the NOWEL network
Presenter: Julia Roeper
Session: Poster Display session 1
Resources:
Abstract
4154 - TP53 mutations predicts worse prognosis in EGFR-mutated NSCLC patients receiving TKIs in first- or further line of treatment
Presenter: Matteo Canale
Session: Poster Display session 1
Resources:
Abstract
1175 - HER3 ligand heregulin expression and clinical implication in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors
Presenter: Kimio Yonesaka
Session: Poster Display session 1
Resources:
Abstract